Gloomy outlook for FY21; R&D setbacks worrisome
19/02/21 -"Along the near-to mid-term headwinds — pandemic-related disruptions and rising competition — the dividend cut from FY22 onwards is also a cause of worry. Thus, we trim our target price by 11%."
Pages
66
Language
English
Published on
19/02/21
You may also be interested by these reports :
17/04/24
Q1 sales exceeded expectations, driven by a strong performance from the Companion Animal segment. The Farm Animal segment was however held back by a ...
16/04/24
Preview: Positive 1Q24 driven by clinical developments of portfolio companies
15/04/24
Investor appetite for Merck KGaA (Add, Germany) shares has been somewhat subdued since we last teased the name (15/03/2021). At that time, the ...
15/04/24
Turnaround story on track – TP increased to CHF 30.00 (from CHF 25.00) – Add reiterated